Robin is the Founder and Chairman of BioMap. Since founding his last start-up, Baidu, in January 2000, Robin has built the company into China’s largest search engine alongside a world-leading Artificial Intelligence platform company.

Wei is a technology enthusiast who is inspired by building cutting-edge technologies to improve industrial efficiency. Spanning his twenty-year technology investment career, Wei has served as General Partner of Legend Star Ventures and the Founding CEO of Baidu Ventures. He has invested and incubated 300 early-stage global technology companies, including more than 50 AI for Life Science-related companies.

Prof. Song is a famous graph network expert and has extensive experience in AI technology and engineering. He held a tenured professorship in the School of Computer Science at Georgia Institute of Technology and served as the deputy director of the Machine Learning Centre. He was the Head of the Deep Learning team at Ant Financial and a researcher at the DAMO Academy.

Since 2008, Prof. Song initiated research in bio-computing at CMU and has achieved a series of breakthrough results in target discovery and drug design using machine learning methods. He has won many Best Paper awards in major machine learning conferences, such as NeurIPS, ICML and AISTATS. As a leading artificial intelligence scholar, he has served as the Program Chair of ICML and different chair-ships of NeurIPS, ICML, ICLR, AAAI and IJCAI, the associate editor of JMLR and IEEE TPAMI, and a board member of the International Machine Learning Conference. He was also a researcher at Google and a postdoctoral researcher at CMU.

Google Scholar

Vicky is our SVP for corporate development, oversees strategy, global partnership and investor relations. She is also the Chief of Staff and leads the company-wide project management efforts.

Prior to joining BioMap as a founding team member, Vicky has vast experience in healthcare and biotech investment. Her career as Vice President of Investments at Baidu Ventures and extensive deal experience at GL Capital provided significant exposure to the industry dynamics and helped foster her critical thinking with regards to frontier exploration.

Vicky is a CFA Charter-holder and received her M.Sc. in Finance and B.Sc. in Life Science from Tsinghua University.

Per is leading our efforts in computational protein design.

Prior to joining BioMap, Per spent several years at Novo Nordisk, where he was Vice President for Computational Drug Design and also served as an interim VP for Research Engineering.. Per established and led the De Novo Protein Design Group of Novo Nordisk, driving significant advancements in protein engineering and discovery. He was part of multiple protein engineering programs and achieved notable successes, including Mim8 which is currently in Phase 3.

Per has also benefitted from experience in startups including Enevolv (now Gingko Bioworks) who he joined in 2019 in Boston, specializing in protein engineering, and was part of engineering SYNB1934 (Phase III).

Per received his bachelor’s degree in Biochemistry and master’s degree in Bioinformatics from the University of Copenhagen. He started his PhD in quantum mechanics, neural networks, and protein folding but he quickly pivoted his research area to computational protein design. In 2012 Per went to the University of Washington to focus on computational protein design of metalloproteins in David Baker’s Lab where he led work on the evolution of enzymes and small molecule binders..

Andy Deng spearheads the company’s AI solution strategy, operation, and development, leveraging industry-leading AI models to empower the life science industry.

Andy has nearly two decades of experience in business management and software commercialization. Prior to BioMap, he spent 16 years at SAP, where he held various leadership roles, including Account Manager, Sales Director, China Vice President, and Global Vice President. During his tenure at SAP, he played a key role in driving significant growth across diverse sectors and crafting successful digital transformation projects for leading companies. These contributions solidified SAP’s position as an industry leader in China.

At Kingdee Software Group, Andy served as Vice President of the company and General Manager of the Large Enterprise Business Group. He oversaw and transformed their large enterprise business, successfully led the creation of several digital transformation projects for many Fortune 500 companies, which significantly impacted Kingdee’s growth.

Andy holds an EMBA degree from the University of Mannheim in Germany.

Robert Gentleman is a world-renowned statistician and bioinformatician, who is recognized, along with Ross Ihaka, as one of the originators of the R programming language, and the Bioconductor project.

He is currently the founding Executive Director of the Center for Computational Biomedicine at Harvard Medical School. He was previously vice president of computational biology at 23andMe and senior director of bioinformatics at Roch/Genentech. In recognizing his exceptional work on the R programming language, the Bioconductor project, and his commitment to data and methods sharing，Dr. Gentleman was bestowed the Benjamin Franklin Award in 2008, and he was elected as a fellow of the International Society for Computational Biology and the American Statistical Association in 2014 and 2017.

Michael Wulfsohn, M.D., Ph.D., received his medical training from University of the Witwatersrand in South Africa. He obtained his Ph. D. in biostatistics from Harvard University. During his 20+ years tenure at Gilead Sciences, Michael helped the company grow into one of the world’s top pharmaceutical companies. As Senior Vice President, Michael led the biometrics team providing statistical support for drug development in multiple therapeutic areas, including virology (HIV, HCV, HBV), inflammation, cardiovascular, respiratory and oncology. His strong leadership led to the approval of 20+ novel drugs. In addition, Michael is a passionate advocate of leveraging AI and multiple omics tools for drug discovery. Under his visionary leadership Gilead Sciences built strong scientific capabilities in genomics and bioinformatics and leveraged a successful data-driven model to develop first-in-class medicines.